| This report contains COVID-19 specific updates.
Gastrointestinal Drugs Investment Competitor Outlook 2020: Covid 19 Impact and Recovery
Report Highlights
Including: Antiulcerants; Vitamin And Minerals; Antacids; Antiemetics And Antinauseants; Antiobesity; Antidiarrhoeals
Covering: Bayer AG; Takeda Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd; Johnson & Johnson; Reckitt Benckiser Group plc
Bayer AG was the largest competitor with 11.52% of the market followed by Takeda Pharmaceuticals and Otsuka Pharmaceutical Co., Ltd.
Gastrointestinal Drugs Investment Competitor Outlook 2020: Covid 19 Impact and Recovery provides strategists, marketers and senior management with the critical information they need to assess the global gastrointestinal drugs sector.
Reasons to Purchase
- Fully updated for 2020 including the impact of the Covid 19/ Novel Coronavirus.
- Identify growth segments and opportunities.
- Facilitate decision making on the basis of historic and forecast data and key trends
- Develop strategies based on likely future developments.
- Gain a global perspective on the development of the market.
Description
Gastrointestinal Drugs Investment Competitor Outlook 2020: Covid 19 Impact and Recovery from the Business Research Company covers market characteristics, size and growth for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the gastrointestinal drugs market revenues, covering both the historic growth of the market and forecasting the future.
gastrointestinal drugs market
Scope
Markets Covered: Antiulcerants; Vitamin And Minerals; Antacids; Antiemetics And Antinauseants; Antiobesity; Antidiarrhoeals
Companies: Bayer AG; Takeda Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd; Johnson & Johnson; Reckitt Benckiser Group plc
Geographic scope: Asia Pacific, North America, Western Europe, Eastern Europe, South America, Middle East, Africa
Countries: Australia, China, Hong Kong, India, Indonesia, Japan, South Korea, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam, Canada, USA, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, the UK, Czech Republic, Poland, Romania, Russia, Israel, Saudi Arabia, Turkey, UAE, Egypt, Nigeria, South Africa
Time series: Five years historic and forecast
Data: Market value in $ billions.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Table 1 : Global Gastrointestinal Drugs Market, Historic Market Size, 2015-2019, $ Billion
- Table 2 : Global Gastrointestinal Drugs Market, Forecast Market Size, 2019-2023, $ Billion
- Table 3 : Global Gastrointestinal Drugs Market, Key Competitors Estimated Market Shares, 2019, Percentage (%)
- Table 4 : Bayer – Financial Performance, $ Billion
- Table 5 : Takeda– Financial Performance, $Billion
- Table 6 : Otsuka – Financial Performance, $ Billion
- Table 7 : Gastrointestinal Drugs Market Data Sources
- Figure 1 : Global Gastrointestinal Drugs Market, Historic Market Size, 2015-2019, $ Billion
- Figure 2 : Global Gastrointestinal Drugs Market, Forecast Market Size, 2019-2023, $ Billion
- Figure 3 : Global Gastrointestinal Drugs Key Competitor Estimated Market Shares, 2019, Percentage (%)
- Figure 4 : Bayer – Financial Performance, $ Billion
- Figure 5 : Takeda – Financial Performance, $ Billion
- Figure 6 : Otsuka – Financial Performance, $ Billion
The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.